The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index; 7 of the 203 sources its claims cite were checked for support.
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Open accessAbstract
Cryptococcus spp., in particular Cryptococcus neoformans and Cryptococcus gattii, have an enormous impact on human health worldwide. The global burden of cryptococcal meningitis is almost a quarter of a million cases and 181,000 deaths annually, with mortality rates of 100% if infections remain untreated. Despite these alarming statistics, treatment options for cryptococcosis remain limited, with only three major classes of drugs approved for clinical use. Exacerbating the public health burden is the fact that the only new class of antifungal drugs developed in decades, the echinocandins, displays negligible antifungal activity against Cryptococcus spp., and the efficacy of the remaining therapeutics is hampered by host toxicity and pathogen resistance. Here, we describe the current arsenal of antifungal agents and the treatment strategies employed to manage cryptococcal disease. We further elaborate on the recent advances in our understanding of the intrinsic and adaptive resistance mechanisms that are utilized by Cryptococcus spp. to evade therapeutic treatments. Finally, we review potential therapeutic strategies, including combination therapy, the targeting of virulence traits, impairing stress response pathways and modulating host immunity, to effectively treat infections caused by Cryptococcus spp. Overall, understanding of the mechanisms that regulate anti-cryptococcal drug resistance, coupled with advances in genomics technologies and high-throughput screening methodologies, will catalyse innovation and accelerate antifungal drug discovery. Cryptococcosis is a serious fungal infection for which treatment options are limited. In this Review, Cowen and colleagues discuss the current antifungal treatments available for cryptococcal infections, the challenges in developing new treatments, and ongoing efforts to identify novel therapies.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes the limited current arsenal against cryptococcal infection, the intrinsic and adaptive resistance mechanisms used by *Cryptococcus* spp., and emerging therapeutic strategies. It highlights combination therapy, virulence-factor and stress-response targeting, drug repurposing, and immunotherapy/vaccine approaches as promising but still mostly preclinical or early-clinical directions.
Key findings
- Cryptococcal meningitis causes an estimated 223,100 cases and 181,100 deaths annually, with 100% mortality if untreated; only three major antifungal classes are approved, and echinocandins have negligible activity against *Cryptococcus* spp.
- Resistance involves genomic plasticity, including aneuploidy (most commonly chromosome 1 disomy involving *ERG11* and *AFR1*), hypermutator strains with ~200-fold higher mutation rates, and transposon movement; hypermutator *C. gattii* strains showed a 15% higher rate of flucytosine resistance.
- Morphological changes contribute to resistance: thicker capsules and cell walls increase antifungal resistance, and titan cells are defined by >10 µm size, >4C ploidy, a thick cell wall, and a highly crosslinked capsule; ~20% of fungal cells in mouse lungs can become titan cells.
- The phase III amphotericin B plus flucytosine regimen followed by fluconazole reduced 10-week mortality to 24%, compared with ~70% mortality in many low- and middle-income African countries; repurposed sertraline and tamoxifen failed to improve outcomes in later trials.
Methods
- Narrative review synthesizing published literature on cryptococcal treatment, antifungal resistance mechanisms, drug discovery, and immunotherapy; no primary experimental data are reported.
- Evidence discussed includes clinical trials, mouse infection models, genomic and chemical-genetic screens, and high-throughput compound screens, such as >300,000 compounds screened for fungicidal activity and ~3,600 bioactive compounds tested for synergy.
- No systematic search strategy, inclusion criteria, or meta-analysis is described.
Limitations
- Stated in the paper: treatment is limited by intrinsic echinocandin resistance, azole resistance, amphotericin B toxicity, flucytosine resistance and monotherapy limitations, and poor access/cost in resource-limited settings; several promising agents remain preclinical or have failed clinical trials, and 18B7 showed poor cerebrospinal fluid penetration.
- Evident from the text: as a narrative review, it does not provide a systematic or quantitative synthesis, and its conclusions depend on the selected cited literature rather than a predefined review protocol.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Not checked yet · 4 No basis given · 3 Partly supported · 1 Supported · 1 Own interpretation · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“most commonly involving disomy of chromosome 1, which contains ERG11 and the predominant efflux pump gene AFR1 (ref.17).”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Partly supportedcites [17] Sionov, E., Lee, H., Chang, Y. C. & Kwon-Chung, K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6, e1000848 (2010). sourceExperimental — accuracy not yet measured
The Results section ('ERG11 is important for chromosome 1 duplication under azole stress'; page unavailable) says chromosome 1 was universally duplicated in the resistant clones studied and identifies ERG11 and AFR1 on that chromosome. It describes AFR1 as an ABC transporter important in azole susceptibility, but does not establish that AFR1 is the predominant efflux pump. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“hypermutator isolates derived from both the clinic and the laboratory lead to the rapid emergence of resistance to drugs such as rapamycin, FK506 (ref.33), flucytosine32, fluconazole and even amphotericin B30.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Supportedcites [30] Boyce, K. J. et al. Mismatch repair of DNA replication errors contributes to microevolution in the pathogenic fungus Cryptococcus neoformans. mBio 8, e00595-17 (2017). This report is one of the first of a hypermutator strain in clinical isolates, which has a fitness advantage owing to mutations in mismatch repair genes. source
The Results section reports rapid emergence of fluconazole- and amphotericin B-resistant colonies in laboratory mismatch-repair mutants, and increased spontaneous fluconazole resistance in the clinical isolate C23. In the citing sentence, this paper is cited for fluconazole and amphotericin B; rapamycin, FK506, and flucytosine have other citations. The paper does not show amphotericin B resistance in the clinical isolates. (LLM, conf=0.89)
- Supportedcites [32] Billmyre, R. B., Applen Clancey, S., Li, L. X., Doering, T. L. & Heitman, J. 5-Fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nat. Commun. 11, 127 (2020). source
The Results section (“Hypermutation mediates resistance to 5FC”) reports that engineered msh2 deletion mutants and naturally occurring hypermutator strains acquired flucytosine (5FC) resistance at elevated rates. The citation to this paper is attached to flucytosine; the other drugs have separate citations in the citing sentence. (LLM, conf=0.92)
- Supportedcites [33] Billmyre, R. B., Clancey, S. A. & Heitman, J. Natural mismatch repair mutations mediate phenotypic diversity and drug resistance in Cryptococcus deuterogattii. eLife 6, e28802 (2017). source
The citation is attached to FK506, not to the later drugs, which have separate citations. In Results, the paper reports that a hypermutator rapidly acquired resistance under FK506/rapamycin exposure at 37°C; it also reports elevated resistance rates in a naturally occurring hypermutator and laboratory-created msh2 mutants. The copy provides no page numbers for these passages. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a 2020 report linked transposons to drug resistance in C. neoformans38.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Partly supportedcites [38] Gusa, A. et al. Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. Proc. Natl Acad. Sci. USA 117, 9973–9980 (2020). This paper is the first description of transposon-mediated antifungal resistance in Cryptococcus spp. sourceExperimental — accuracy not yet measured
The Introduction reports that transposable elements caused most of the drug-resistance mutations studied, supporting the link. But it identifies the experimental organism as C. deneoformans and distinguishes it from C. neoformans; the claim names the wrong species. (LLM, conf=0.89)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“a subset of Cryptococcus isolates have been identified as hypermutator strains30,31, which contain mutations in core genes in the DNA mismatch repair pathway, most notably MSH2 (refs30,32,33)”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [30] Boyce, K. J. et al. Mismatch repair of DNA replication errors contributes to microevolution in the pathogenic fungus Cryptococcus neoformans. mBio 8, e00595-17 (2017). This report is one of the first of a hypermutator strain in clinical isolates, which has a fitness advantage owing to mutations in mismatch repair genes. source
- Not checked yetcites [31] Boyce, K. J., Cao, C., Xue, C. & Idnurm, A. A spontaneous mutation in DNA polymerase POL3 during in vitro passaging causes a hypermutator phenotype in Cryptococcus species. DNA Repair 86, 102751 (2020). source
- Not checked yetcites [32] Billmyre, R. B., Applen Clancey, S., Li, L. X., Doering, T. L. & Heitman, J. 5-Fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nat. Commun. 11, 127 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“a mutation in the proofreading domain of POL3 (encoding the catalytic subunit of DNA polymerase δ) was also shown to confer the hypermutator phenotype31.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [31] Boyce, K. J., Cao, C., Xue, C. & Idnurm, A. A spontaneous mutation in DNA polymerase POL3 during in vitro passaging causes a hypermutator phenotype in Cryptococcus species. DNA Repair 86, 102751 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Laboratory studies have shown that selection for resistance to environmental agrochemicals, primarily through the upregulation of the azole target gene ERG11 and drug efflux pumps, can lead to cross-resistance to clinically deployed antifungals19,20.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms
What the sources say
- Not checked yetcites [19] Bastos, R. W. et al. From the environment to the host: how non-azole agrochemical exposure affects the antifungal susceptibility and virulence of Cryptococcus gattii. Sci. Total Environ. 681, 516–523 (2019). source
- Not checked yetcites [20] Bastos, R. W. et al. Environmental triazole induces cross-resistance to clinical drugs and affects morphophysiology and virulence of Cryptococcus gattii and C. neoformans. Antimicrob. Agents Chemother. 62, e01179-17 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This phenomenon was first described in 1999, when researchers observed that a subset of Cryptococcus cells were able to grow at azole concentrations well above the inhibitory concentration in vitro21.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [21] Mondon, P. et al. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43, 1856–1861 (1999). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, hypermutator phenotypes can also result from mutations in other genes, such as MSL1 and PMS1 (ref.30).”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [30] Boyce, K. J. et al. Mismatch repair of DNA replication errors contributes to microevolution in the pathogenic fungus Cryptococcus neoformans. mBio 8, e00595-17 (2017). This report is one of the first of a hypermutator strain in clinical isolates, which has a fitness advantage owing to mutations in mismatch repair genes. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Disomy of chromosome 4 is the second most common aneuploidy conferring azole heteroresistance, which is largely attributed to three genes: SEY1, which encodes a GTPase, and GLO3 and GCS2, which encode ADP-ribosylation factor proteins25.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [25] Ngamskulrungroj, P. et al. Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS ONE 7, e33022 (2012).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Heteroresistance primarily occurs through the formation of aneuploid cells, both in vitro and in vivo17,22,24 (Fig. 1)”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [17] Sionov, E., Lee, H., Chang, Y. C. & Kwon-Chung, K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6, e1000848 (2010). source
- Not checked yetcites [22] Stone, N. R. et al. Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. J. Clin. Invest. 129, 999–1014 (2019). This paper presents the first clinical samples to demonstrate fluconazole heteroresistance due to aneuploidy, achieved through increased efflux levels. source
- Not checked yetcites [24] Sionov, E., Chang, Y. C. & Kwon-Chung, K. J. Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob. Agents Chemother. 57, 5127–5130 (2013). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 5
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These traits can be inherited, and are often transient, such that they are lost when the stress is removed17,18.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms
What the sources say
- Supportedcites [17] Sionov, E., Lee, H., Chang, Y. C. & Kwon-Chung, K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6, e1000848 (2010). source
The Introduction describes fluconazole-induced chromosome duplications that confer adaptive resistance and are lost after repeated transfer in drug-free media. The Results report resistant clones maintained over many generations and show that removing drug pressure led to sequential loss of duplicated chromosomes and a return to the original tolerance level. This supports inheritance and transience in the studied C. neoformans response to fluconazole. (LLM, conf=0.88)
- Partly supportedcites [18] Sionov, E., Chang, Y. C., Garraffo, H. M. & Kwon-Chung, K. J. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob. Agents Chemother. 53, 2804–2815 (2009). sourceExperimental — accuracy not yet measured
The Abstract describes fluconazole heteroresistance in C. neoformans as a reversible adaptive response and says resistant subpopulations yield pure cultures of resistant cells. The Results report that resistance persisted across transfers but usually reverted to the original heteroresistance level in drug-free medium. This supports a transient, transmissible resistance phenotype, but not the broader claim that traits of genomic plasticity and physiological adaptability generally behave this way; the underlying heteroresistance was not lost. (LLM, conf=0.83)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Aneuploidy has been reported for other chromosomes, including chromosomes 6, 10, 11 and 14, although the specific genetic elements responsible for the selective advantage remain unclear17,22,25,26.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [17] Sionov, E., Lee, H., Chang, Y. C. & Kwon-Chung, K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6, e1000848 (2010). source
- Not checked yetcites [22] Stone, N. R. et al. Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. J. Clin. Invest. 129, 999–1014 (2019). This paper presents the first clinical samples to demonstrate fluconazole heteroresistance due to aneuploidy, achieved through increased efflux levels. source
- Not checked yetcites [25] Ngamskulrungroj, P. et al. Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS ONE 7, e33022 (2012).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A new form of encochleated oral amphotericin B (CAmB), where amphotericin B is encapsulated in a lipid-containing crystal nanoparticle, is effectively delivered to the central nervous system and displays antifungal efficacy in a mouse model11.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [11] Lu, R. et al. Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. mBio 10, e00724-19 (2019).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The phase III trial reported 10-week mortality of 24%, which is a considerable improvement compared with the current ~70% mortality rate in many low- and middle-income countries in Africa6,14.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [6] Rajasingham, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect. Dis. 17, 873–881 (2017). source
- Not checked yetcites [14] Molloy, S. F. et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N. Engl. J. Med. 378, 1004–1017 (2018). This seminal study provides guidelines adopted by the WHO for combatting cryptococcal infections. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a clinical trial with patients who are HIV-positive and suffering from cryptococcal meningitis showed that the combination of amphotericin B with the fluorinated pyrimidine analogue flucytosine, followed by the triazole fluconazole, improved survival rates compared with amphotericin B alone and minimized toxic effects13.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [13] Day, J. N. et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368, 1291–1302 (2013). This important clinical trial shows that the combination of amphotericin B and flucytosine improves survival of patients with cryptococcal meningitis. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“An estimated 223,100 cases of cryptococcal meningitis occur globally each year, leading to 181,100 deaths6.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
What the sources say
- Not checked yetcites [6] Rajasingham, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect. Dis. 17, 873–881 (2017). source
hedgeddirectn = 223,100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These mutations result in an ~200-fold higher mutation rate than in standard laboratory strains30 and preferentially affect genes containing homopolymer runs33.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [30] Boyce, K. J. et al. Mismatch repair of DNA replication errors contributes to microevolution in the pathogenic fungus Cryptococcus neoformans. mBio 8, e00595-17 (2017). This report is one of the first of a hypermutator strain in clinical isolates, which has a fitness advantage owing to mutations in mismatch repair genes. source
- Not checked yetcites [33] Billmyre, R. B., Clancey, S. A. & Heitman, J. Natural mismatch repair mutations mediate phenotypic diversity and drug resistance in Cryptococcus deuterogattii. eLife 6, e28802 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This increase in chitin induces a T helper 2-type allergic response and cytokine release, rather than a protective T helper 1-type response, which leads to increased mortality in infected mice152.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Morphological alterations
What the sources say
- Not checked yetcites [152] Wiesner, D. L. et al. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog. 11, e1004701 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“C. neoformans cells with thicker capsules exhibit amphotericin B resistance and enhanced virulence40,41”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Morphological alterations
What the sources say
- Not checked yetcites [40] Cordoba, S., Afeltra, J. & Vitale, R. G. Evaluation of the in vitro activity of amphotericin B by time-kill curve methodology against large and small capsulate C. neoformans isolates. Diagn. Microbiol. Infect. Dis. 71, 260–262 (2011). source
- Not checked yetcites [41] Park, Y. D. et al. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule. PLoS Pathog. 10, e1004037 (2014).
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A genetic screen of more than 10,000 C. neoformans mutants provided insight into this inherent resistance46. This screen identified CDC50 (encoding the β-subunit of a lipid flippase enzyme) as integral to echinocandin resistance and further demonstrated its involvement in maintaining lipid asymmetry of the phospholipid membrane46.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Intrinsic resistance to echinocandins
What the sources say
- Not checked yetcites [46] Huang, W. et al. Lipid flippase subunit Cdc50 mediates drug resistance and virulence in Cryptococcus neoformans. mBio 7, e00478-16 (2016). This paper provides foundational genetic insights into the intrinsic echinocandin resistance of Cryptococcus. source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This transition can be triggered by the bacterial peptidoglycan subunit muramyl dipeptide in serum and is regulated by USV101 (ref.149) as well as STE3a and GPR5 (ref.150), which converge on the cAMP–PKA pathway149,150.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Morphological alterations
What the sources say
- Not checked yetcites [149] Dambuza, I. M. et al. The Cryptococcus neoformans titan cell is an inducible and regulated morphotype underlying pathogenesis. PLoS Pathog. 14, e1006978 (2018). source
- Not checked yetcites [150] Okagaki, L. H. et al. Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot. Cell 10, 1306–1316 (2011). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“On titan cell formation, the polysaccharide capsule surrounding Cryptococcus cells becomes condensed and highly crosslinked151; the cell wall can increase in thickness from 50–100 nm to 2–3 µm (ref.147), and the cell wall composition is altered through an increase in chitin content and a decrease in glucan152.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Morphological alterations
What the sources say
- Not checked yetcites [147] Zaragoza, O. et al. Fungal cell gigantism during mammalian infection. PLoS Pathog. 6, e1000945 (2010). source
- Not checked yetcites [151] Mukaremera, L. et al. Titan cell production in Cryptococcus neoformans reshapes the cell wall and capsule composition during infection. Cell Surf. 1, 15–24 (2018). source
- Not checked yetcites [152] Wiesner, D. L. et al. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog. 11, e1004701 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cdc50 directly interacts with Crm1 and negatively regulates its expression47.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Intrinsic resistance to echinocandins
What the sources say
- Not checked yetcites [47] Cao, C., Wang, Y., Husain, S., Soteropoulos, P. & Xue, C. A mechanosensitive channel governs lipid flippase-mediated echinocandin resistance in Cryptococcus neoformans. mBio 10, e01952-19 (2019).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Despite these alarming statistics, treatment options for cryptococcosis remain limited, with only three major classes of drugs approved for clinical use.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Scarcity of these two drugs has resulted in the widespread use of the much less effective fluconazole monotherapy, which explains the dramatically high mortality rate in these low- and middle-income African countries4,7.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [4] Perfect, J. R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291–322 (2010). source
- Not checked yetcites [7] Loyse, A. et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect. Dis. 19, e143–e147 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“immunocompromised individuals are most vulnerable, but there are also reports of cryptococcal infections in immunocompetent hosts4,5”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
What the sources say
- Not checked yetcites [4] Perfect, J. R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291–322 (2010). source
- Not checked yetcites [5] Kwon-Chung, K. J. et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb. Perspect. Med. 4, a019760 (2014). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment options for invasive cryptococcal infection are limited, given that Cryptococcus spp. are intrinsically resistant to echinocandins and that they employ an arsenal of defences that enable resistance to azoles2,8.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [2] Lee, Y., Puumala, E., Robbins, N. & Cowen, L. E. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem. Rev. https://doi.org/10.1021/acs.chemrev.0c00199 (2020). source
- Not checked yetcites [8] Denning, D. W. Echinocandin antifungal drugs. Lancet 362, 1142–1151 (2003). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In low- and middle-income countries, flucytosine is not available owing to market failure and lack of in-country registration, whereas access to amphotericin B and its liposomal form is limited due to the high cost and lack of safe intravenous administration7.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [7] Loyse, A. et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect. Dis. 19, e143–e147 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“C. neoformans and Cryptoccocus gattii are the major species responsible for life-threatening cryptococcal meningitis”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Heteroresistance has major clinical implications, as the proportion of resistant cells increases over the course of therapy, making this mechanism a major contributor to relapse during azole maintenance therapy22,23.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [22] Stone, N. R. et al. Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. J. Clin. Invest. 129, 999–1014 (2019). This paper presents the first clinical samples to demonstrate fluconazole heteroresistance due to aneuploidy, achieved through increased efflux levels. source
- Not checked yetcites [23] Rhodes, J. et al. A population genomics approach to assessing the genetic basis of within-host microevolution underlying recurrent cryptococcal meningitis infection. G3 7, 1165–1176 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the polyene amphotericin B has been the primary treatment for cryptococcal infection for more than half a century, despite the fact that it causes substantial toxicity and that its availability is limited by economic and logistical constraints2,4”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Treatments for cryptococcal infections
What the sources say
- Not checked yetcites [2] Lee, Y., Puumala, E., Robbins, N. & Cowen, L. E. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem. Rev. https://doi.org/10.1021/acs.chemrev.0c00199 (2020). source
- Not checked yetcites [4] Perfect, J. R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291–322 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Cryptococcus polysaccharide capsule modulates immune responses, enhances pathogenicity and confers protection against oxidative stress55,56.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“this rapid genome alteration resulting in aneuploid cells has been proposed as an alternative mechanism of heteroresistance43.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Morphological alterations
What the sources say
- Not checked yetcites [43] Zafar, H., Altamirano, S., Ballou, E. R. & Nielsen, K. A titanic drug resistance threat in Cryptococcus neoformans. Curr. Opin. Microbiol. 52, 158–164 (2019). This seminal review summarizes the current understanding of the mechanisms underlying antifungal resistance of the Cryptococcus titan cell. source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“transposon-driven mutagenesis was enhanced in multiple strains at 37 °C compared with that at 30 °C, suggesting that the body temperature of a mammalian host may amplify this phenomenon38.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Antifungal resistance mechanisms > Genomic plasticity
What the sources say
- Not checked yetcites [38] Gusa, A. et al. Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. Proc. Natl Acad. Sci. USA 117, 9973–9980 (2020). This paper is the first description of transposon-mediated antifungal resistance in Cryptococcus spp. source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“enabling the design of APX879, an FK506 analogue with an acetohydrazine substitution of the C22 carbonyl, which has 70-fold lower immunosuppressive effects than FK506 while retaining antifungal activity77”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Stress responses
What the sources say
- Not checked yetcites [77] Juvvadi, P. R. et al. Harnessing calcineurin–FK506–FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. Nat. Commun. 10, 4275 (2019). This paper presents an excellent example of successful structure-guided drug design to develop fungal-specific calcineurin inhibitors. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Melanin is produced by laccases, which are upregulated in C. neoformans clinical and environmental isolates66”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [66] Lahiri, S. et al. In vitro expression of vital virulent genes of clinical and environmental isolates of Cryptococcus neoformans/gattii in endothelial cells of human blood–brain barrier. J. Mycol. Med. 29, 239–244 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The fungal cell wall is a dynamic structure that is important not only for cell integrity but also for modulating the host immune response39.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [39] Garcia-Rubio, R., de Oliveira, H. C., Rivera, J. & Trevijano-Contador, N. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front. Microbiol. 10, 2993 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Deletion of the gene encoding either of these enzymes impairs capsule linkage and reduces the fungal burden in infections in mice41,57.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [41] Park, Y. D. et al. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule. PLoS Pathog. 10, e1004037 (2014).
- Not checked yetcites [57] Klutts, J. S. & Doering, T. L. Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. J. Biol. Chem. 283, 14327–14334 (2008). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, phospholipase B1 (encoded by PLB1) facilitates Cryptococcus adherence to and invasion of the host cell, contributes to fungal cell wall integrity and degrades host cell membranes, thereby providing nutrients that support fungal survival69,70.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [69] Wright, L. C. et al. Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids. Eukaryot. Cell 6, 37–47 (2007). source
- Not checked yetcites [70] Siafakas, A. R. et al. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J. Biol. Chem. 282, 37508–37514 (2007). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The C. neoformans homologue of mTOR kinase, Tor1, is essential for Cryptococcus stress response signalling, virulence84,85 and fluconazole tolerance (that is, the ability of a drug-susceptible organism to grow in the presence of an antifungal drug at concentrations above the minimum inhibitory concentration)86.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Stress responses
What the sources say
- Not checked yetcites [84] Lee, H., Khanal Lamichhane, A., Garraffo, H. M., Kwon-Chung, K. J. & Chang, Y. C. Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans. Mol. Microbiol. 84, 130–146 (2012). source
- Not checked yetcites [85] So, Y. S., Lee, D. G., Idnurm, A., Ianiri, G. & Bahn, Y. S. The TOR pathway pays pleiotropic roles in growth and stress responses of the fungal pathogen Cryptococcus neoformans. Genetics 212, 1241–1258 (2019). source
- Not checked yetcites [86] Berman, J. & Krysan, D. J. Drug resistance and tolerance in fungi. Nat. Rev. Microbiol. 18, 319–331 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“An inhibitor of Hsp90 with 25-fold greater selectivity for Candida albicans Hsp90 than for human HSP90 (ref.81) and aminopyrazole-substituted resorcylate amides with more than 30-fold greater selectivity for C. neoformans Hsp90 than for human HSP90 (ref.82) have been identified”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Stress responses
What the sources say
- Not checked yetcites ref.81
- Not checked yetcites ref.82
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Finally, the secreted peptide Qsp1 is an important virulence determinant that acts as an autoregulatory signalling molecule and is transported into the fungal cell through Opt1 to initiate a diverse transcriptional response, including the production of proteases and activation of cell wall integrity72,73.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [72] Lee, H., Chang, Y. C., Nardone, G. & Kwon-Chung, K. J. TUP1 disruption in Cryptococcus neoformans uncovers a peptide-mediated density-dependent growth phenomenon that mimics quorum sensing. Mol. Microbiol. 64, 591–601 (2007). source
- Not checked yetcites [73] Homer, C. M. et al. Intracellular action of a secreted peptide required for fungal virulence. Cell Host Microbe 19, 849–864 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In particular, melanin is a major virulence factor that protects fungal cells from oxidative damage, antifungal assault and high temperature, and also modulates host immune responses39.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [39] Garcia-Rubio, R., de Oliveira, H. C., Rivera, J. & Trevijano-Contador, N. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front. Microbiol. 10, 2993 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Hsp90 inhibition has been shown to impair C. neoformans virulence traits, such as capsule assembly, and increase susceptibility to antifungal agents79,80.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Stress responses
What the sources say
- Not checked yetcites [79] Chatterjee, S. & Tatu, U. Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans. PLoS Negl. Trop. Dis. 11, e0005836 (2017). source
- Not checked yetcites [80] Cordeiro, R. A. et al. Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex. Microbiology 162, 309–317 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Deletion of CAP10, CAP60 and PXB1 not only blocks capsule production but also leads to attenuated virulence52,58.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Potential therapeutic targets > Virulence factors
What the sources say
- Not checked yetcites [52] Liu, O. W. et al. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135, 174–188 (2008). source
- Not checked yetcites [58] Almeida, F., Wolf, J. M. & Casadevall, A. Virulence-associated enzymes of Cryptococcus neoformans. Eukaryot. Cell 14, 1173–1185 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“but mefloquine derivatives have been identified that have improved in vitro antifungal activity and that impede C. neoformans capsule formation and melanization104.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [104] Montoya, M. C., Beattie, S., Alden, K. M. & Krysan, D. J. Derivatives of the antimalarial drug mefloquine are broad-spectrum antifungal molecules with activity against drug-resistant clinical isolates. Antimicrob. Agents Chemother. 64, e02331-19 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Another example is the macrolides, commonly used antibiotics that target protein synthesis, which reduce capsule formation in C. gattii, impairing this key virulence trait and resulting in enhanced phagocytosis and inflammatory cytokine production by macrophages in culture59.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [59] Nakamura, S. et al. Macrolides inhibit capsule formation of highly virulent Cryptococcus gattii and promote innate immune susceptibility. Antimicrob. Agents Chemother. 63, e02364-18 (2019).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clinical trials with APX001 for the treatment of cryptococcosis are starting imminently, and phase II trials for the treatment of invasive infections caused by Aspergillus spp. and Candida spp. are currently underway (NCT02957929, NCT02956499 and NCT04240886)”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Promising chemical matter
What the sources say
- Not checked yetcites NCT02957929
- Not checked yetcites NCT02956499
- Not checked yetcites NCT04240886
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Gwt1, an important virulence factor and the enzyme responsible for catalysing an early step in glycosylphosphatidylinositol (GPI)-anchor biosynthesis96, has also emerged as a promising antifungal target.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Promising chemical matter
What the sources say
- Not checked yetcites [96] Zhao, Q. et al. GWT1 encoding an inositol acyltransferase homolog is required for laccase repression and stress resistance in the basidiomycete Cryptococcus neoformans. FEMS Yeast Res. 15, fov086 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Similarly, tamoxifen, an oestrogen receptor modulator that is used to treat and prevent breast cancer and osteoporosis, also displayed potent anti-cryptococcal activity in vitro106 and in a mouse model of disseminated cryptococcosis107.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [106] Dolan, K. et al. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53, 3337–3346 (2009). source
- Not checked yetcites [107] Butts, A. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 5, e00765-13 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Of these 31 molecules, the largest class of inhibitors identified were antipsychotic agents, with general antiseptic agents following close behind111.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [111] Butts, A. et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 12, 278–287 (2013). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similar to other clinically approved azoles, VT-1598 displays broad-spectrum activity against diverse fungi, including a strong therapeutic potential in a mouse model of cryptococcal meningitis101.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Promising chemical matter
What the sources say
- Not checked yetcites [101] Garvey, E. P., Sharp, A. D., Warn, P. A., Yates, C. M. & Schotzinger, R. J. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J. Antimicrob. Chemother. 73, 2815–2822 (2018). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fenbendazole displays potent in vitro activity against C. neoformans and C. gattii, as well as in vivo activity in a mouse model of cryptococcosis103.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [103] de Oliveira, H. C. et al. Fenbendazole controls in vitro growth, virulence potential, and animal infection in the Cryptococcus model. Antimicrob. Agents Chemother. 64, e00286-20 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A high-throughput screen of >300,000 compounds from the US National Institutes of Health (NIH) Molecular Libraries Program was undertaken to identify agents with fungicidal activity against C. neoformans, where secondary assays prioritized compounds that interfered with fungal cell wall integrity91.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Promising chemical matter
What the sources say
- Not checked yetcites [91] Hartland, K. et al. High-throughput screen in Cryptococcus neoformans identifies a novel molecular scaffold that inhibits cell wall integrity pathway signaling. ACS Infect. Dis. 2, 93–102 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Systematic analysis of these apparently inactive compounds revealed that they are not biologically inert, and even identified a potent inhibitor of C. neoformans growth in vitro87.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Promising chemical matter
What the sources say
- Not checked yetcites [87] Wassermann, A. M. et al. Dark chemical matter as a promising starting point for drug lead discovery. Nat. Chem. Biol. 11, 958–966 (2015). This paper reaffirms that dark chemical matter compounds can be attractive lead compounds and demonstrates the potential for anti-cryptococcal drug discovery. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Most compound libraries have been designed to maximize drug-like properties with respect to mammalian targets and physiology, whereas antifungal drugs require unique physicochemical properties.
In the paper
“The efficacy of fenbendazole was attributed to its growth-inhibitory properties, its inhibition of Cryptococcus virulence determinants and its inhibition of fungal proliferation inside macrophages103.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [103] de Oliveira, H. C. et al. Fenbendazole controls in vitro growth, virulence potential, and animal infection in the Cryptococcus model. Antimicrob. Agents Chemother. 64, e00286-20 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Combination therapy has the potential to confer enhanced efficacy and fungal selectivity while reducing vulnerability to the evolution of resistance2.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Drug combination therapy
What the sources say
- Not checked yetcites [2] Lee, Y., Puumala, E., Robbins, N. & Cowen, L. E. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem. Rev. https://doi.org/10.1021/acs.chemrev.0c00199 (2020). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The amphipathic nature of this motif permits the crossing of biological membranes, a property that is important for traversing the blood–brain barrier and accessing cryptococcal cells that reside within the lysosome or phagolysosome of host cells114.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Repurposing old drugs
What the sources say
- Not checked yetcites [114] Banks, W. A. Characteristics of compounds that cross the blood–brain barrier. BMC Neurol. 9, S3 (2009). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Heat-killed mutant strains have also been reported to induce strong T helper 1 cell responses, resulting in full protection against C. neoformans challenge65,136.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Immunotherapy and vaccine development
What the sources say
- Not checked yetcites [65] Upadhya, R. et al. Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans. mBio 7, e00547-16 (2016). source
- Not checked yetcites [136] Zhai, B. et al. Development of protective inflammation and cell-mediated immunity against Cryptococcus neoformans after exposure to hyphal mutants. mBio 6, e01433-15 (2015). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Specifically, mice vaccinated with glucan particles containing cryptococcal antigens mounted antigen-specific T cell responses and sustained protection against cryptococcosis138.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Immunotherapy and vaccine development
What the sources say
- Not checked yetcites [138] Specht, C. A. et al. Vaccination withrecombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse atrain and cryptococcal species. mBio 8, e01872-17 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Similar protective effects were seen with an avirulent but live mutant strain of C. neoformans lacking sterylglucosidase (sglΔ)134,135.”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Immunotherapy and vaccine development
What the sources say
- Not checked yetcites [134] Wormley, F. L. Jr., Perfect, J. R., Steele, C. & Cox, G. M. Protection against cryptococcosis by using a murine γ interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75, 1453–1462 (2007). source
- Not checked yetcites [135] Rella, A. et al. Role of sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front. Microbiol. 6, 836 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
The paper relies on this without support.
Virulence factors are not required for the growth of the pathogen but are crucial for causing disease.
“Targeting virulence factors, which are not required for the growth of the pathogen but, instead, are crucial for causing disease, opens up a plethora of new targets for drug development.”
The paper relies on this without support.
The fungal cell wall is absent from mammalian cells.
“This structure is absent from mammalian cells, and therefore great efforts have been made to develop antifungal agents that target this unique structure directly or that impair its biosynthesis.”
The paper relies on this without support.
Most compound libraries have been designed to maximize drug-like properties with respect to mammalian targets and physiology, whereas antifungal drugs require unique physicochemical properties.
“The development of new antifungal molecules remains a considerable challenge, as most compound libraries have been designed to maximize their ‘drug-like’ properties with respect to mammalian targets and physiology, whereas antifungal drugs require unique physicochemical properties, owing in part to the need for these molecules to transverse the fungal cell wall.”
The paper relies on this without support.
Antifungal molecules need good central nervous system penetration and should be able to be administered orally to ensure widespread access within developing countries with limited resources.
“Furthermore, because of the unique neurological features of cryptococcal disease, antifungal molecules are needed that have good central nervous system penetration, and they should be able to be administered orally to ensure widespread access within developing countries with limited resources.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“C. neoformans is intrinsically resistant to echinocandins, and therefore treatment options remain limited to polyenes, azoles, and the pyrimidine analog flucytosine that targets RNA and DNA synthesis (Denning 2003; Iyer et al. 2021).”
From Genetic analysis of Hsp90 function in Cryptococcus neoformans highlights key roles in stress tolerance and virulence (2022) · cites this paper as Iyer et al. 2021
In the citing paper
“C. neoformans is also able to develop resistance to all other current antifungals by employing a plethora of genetic, genomic, and adaptive biological strategies (Iyer et al. 2021).”
From Genetic analysis of Hsp90 function in Cryptococcus neoformans highlights key roles in stress tolerance and virulence (2022) · cites this paper as Iyer et al. 2021
In the citing paper
“Essential genes that are required for survival serve as optimal targets for novel antifungal development (Iyer et al. 2021).”
From Genetic analysis of Hsp90 function in Cryptococcus neoformans highlights key roles in stress tolerance and virulence (2022) · cites this paper as Iyer et al. 2021
In the citing paper
“only a small number of essential genes have been identified and characterized in C. neoformans due to the technical challenges of genetic manipulation in this organism (Ianiri and Idnurm 2015; Iyer et al. 2021).”
From Genetic analysis of Hsp90 function in Cryptococcus neoformans highlights key roles in stress tolerance and virulence (2022) · cites this paper as Iyer et al. 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
“| Monoclonal antibody 18B7 | Binds to the capsular component glucuronoxylomannan | Efficacy displayed in basic research |”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Immunotherapy and vaccine development
“With promising anti-cryptococcal effects in rodent models, 18B7 was evaluated in a phase I/II trial in patients with AIDS-related cryptococcal meningitis132.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
“C. neoformans var. neoformans (serotype D) and C. neoformans var. grubii (serotype A)”
§ Treatment strategies for cryptococcal infection: challenges, advances and future outlook > Introduction
“serotype A isolates comprising var. neoformans (VN) lineages VNI and VNII”
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species
Garcia-Rubio, R., de Oliveira, H. C., Rivera, J., & Trevijano-Contador, N. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02993 · Cited by 917
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Self-citationRecognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex
Hagen, F., Khayhan, K., Theelen, B., Kolecka, A., Polacheck, I., Sionov, E., Falk, R., Parnmen, S., Lumbsch, H. T., & Boekhout, T. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.02.009 · Cited by 723
Characteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Combination Antifungal Therapy for Cryptococcal Meningitis
Day, J., Chau, T. T., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D. T., Phong, N. D., Cao, Q. T., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 542
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis
Kwon-Chung, K. J., Fraser, J. A., Doering, T. L., Wang, Z. A., Janbon, G., Idnurm, A., & Bahn, Y.-S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019760 · Cited by 531
Molecular Typing of IberoAmericanCryptococcus neoformansIsolates
Meyer, W., Castañeda, A., Jackson, S. R., Huynh, M., Castañeda, E., & the IberoAmerican Cryptococcal Study Group (2003) · Emerging infectious diseases · doi:10.3201/eid0902.020246 · Cited by 521
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA
Toffaletti, D. L., Rude, T. H., Johnston, S. A., Durack, D. T., & Perfect, J. R. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.5.1405-1411.1993 · Cited by 488
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, P. R., Jarvis, J. N., Panackal, A. A., Fisher, M. C., Molloy, S. F., Loyse, A., & Harrison, T. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.167 · Cited by 487
Sionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479
Systematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans
Liu, O. W., Chun, C. D., Chow, E. D., Chen, C., Madhani, H. D., & Noble, S. M. (2008) · Cell · doi:10.1016/j.cell.2008.07.046 · Cited by 443
Franzot, S. P., Salkin, I. F., & Casadevall, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.838-840.1999 · Cited by 417
Synergistic Dual Transition Metal Catalysis
Kim, U. B., Jung, D. J., Jeon, H. J., Rathwell, K., & Lee, S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00245 · Cited by 405
The Case for Adopting the “Species Complex” Nomenclature for the Etiologic Agents of Cryptococcosis
Kwon-Chung, K. J., Bennett, J. E., Wickes, B. L., Meyer, W., Cuomo, C. A., Wollenburg, K. R., Bicanic, T. A., Castañeda, E., Chang, Y. C., Chen, J., et al. (2017) · mSphere · doi:10.1128/msphere.00357-16 · Cited by 401
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D. M., Mfinanga, S., Temfack, E., Lakhi, S., Kivuyo, S. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 397
Janbon, G., Ormerod, K. L., Paulet, D., Byrnes, E. J., Yadav, V., Chatterjee, G., Mullapudi, N., Hon, C.-C., Billmyre, R. B., Brunel, F., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004261 · Cited by 380
The benzimidazole anthelmintic agents‐a review
McKELLAR, Q. A., & SCOTT, E. W. (1990) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.1990.tb00773.x · Cited by 371
Jarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367
Cryptococcal cell morphology affects host cell interactions and pathogenicity
Okagaki, L. H., Strain, A. K., Nielsen, J. N., Charlier, C., Baltes, N. J., Chrétien, F., Heitman, J., Dromer, F., & Nielsen, K. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000953 · Cited by 345
Fungal cell gigantism during mammalian infection
Zaragoza, O., García-Rodas, R., Nosanchuk, J. D., Cuenca-Estrella, M., Rodríguez-Tudela, J. L., & Casadevall, A. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000945 · Cited by 311
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298
Jarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276
Basic principles of the virulence of Cryptococcus
Zaragoza, O. (2019) · Virulence · doi:10.1080/21505594.2019.1614383 · Cited by 249
Banks, I. R., Specht, C. A., Donlin, M. J., Gerik, K. J., Levitz, S. M., & Lodge, J. K. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.11.1902-1912.2005 · Cited by 245
Dromer, F., Charreire, J., Contrepois, A., Carbon, C., & Yeni, P. (1987) · Infection and Immunity · doi:10.1128/iai.55.3.749-752.1987 · Cited by 243
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans
Rittershaus, P. C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27890 · Cited by 239
Larsen, R. A., Pappas, P. G., Perfect, J., Aberg, J. A., Casadevall, A., Cloud, G. A., James, R., Filler, S., & Dismukes, W. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.952-958.2005 · Cited by 236
Wiesner, D. L., Specht, C. A., Lee, C. K., Smith, K. D., Mukaremera, L., Lee, S. T., Lee, C. G., Elias, J. A., Nielsen, J. N., Boulware, D. R., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004701 · Cited by 214
Systematic functional profiling of transcription factor networks in Cryptococcus neoformans
Jung, K., Yang, D., Maeng, S., Lee, K.-T., So, Y.-S., Hong, J., Choi, J., Byun, H.-J., Kim, H., Bang, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7757 · Cited by 209
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205
Recombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal Meningitis
Pappas, P. G., Bustamante, B., Ticona, E., Hamill, R. J., Johnson, P. C., Reboli, A., Aberg, J., Hasbun, R., & Hsu, H. H. (2004) · The Journal of Infectious Diseases · doi:10.1086/420829 · Cited by 202
Ikeda, R., Shinoda, T., Fukazawa, Y., & Kaufman, L. (1982) · Journal of Clinical Microbiology · doi:10.1128/jcm.16.1.22-29.1982 · Cited by 200
Titan cells in Cryptococcus neoformans: cells with a giant impact
Zaragoza, Ó., & Nielsen, K. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.006 · Cited by 197
Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., & Kurtz, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.2.444-453.1999 · Cited by 196
Laccase of Cryptococcus neoformans Is a Cell Wall-Associated Virulence Factor
Zhu, X., Gibbons, J., Garcia-Rivera, J., Casadevall, A., & Williamson, P. R. (2001) · Infection and Immunity · doi:10.1128/iai.69.9.5589-5596.2001 · Cited by 188
Wormley, F. L., Perfect, J. R., Steele, C., & Cox, G. M. (2007) · Infection and Immunity · doi:10.1128/iai.00274-06 · Cited by 187
Cryptococcus neoformans Virulence Gene Discovery through Insertional Mutagenesis
Idnurm, A., Reedy, J. L., Nussbaum, J. C., & Heitman, J. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.420-429.2004 · Cited by 185
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183
Dambuza, I. M., Drake, T., Chapuis, A., Zhou, X., Correia, J., Taylor-Smith, L., LeGrave, N., Rasmussen, T., Fisher, M. C., Bicanic, T., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006978 · Cited by 182
Sionov, E., Chang, Y. C., Garraffo, H. M., & Kwon-Chung, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00295-09 · Cited by 179
Maligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
Transposons: the agents of antibiotic resistance in bacteria
Babakhani, S., & Oloomi, M. (2018) · Journal of Basic Microbiology · doi:10.1002/jobm.201800204 · Cited by 175
Systematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans
Lee, K.-T., So, Y.-S., Yang, D., Jung, K.-W., Choi, J., Lee, D., Kwon, H., Jang, J., Wang, L. L., Cha, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12766 · Cited by 172
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none
Barber, D. L., Andrade, B. B., Sereti, I., & Sher, A. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2712 · Cited by 169
Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation
Gerstein, A. C., Fu, M. S., Mukaremera, L., Li, Z., Ormerod, K. L., Fraser, J. A., Berman, J., & Nielsen, K. (2015) · mBio · doi:10.1128/mbio.01340-15 · Cited by 167
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., Segal, E. S., Needleman, L., Molloy, S. F., Kwon-Chung, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124516 · Cited by 167
Rachini, A., Pietrella, D., Lupo, P., Torosantucci, A., Chiani, P., Bromuro, C., Proietti, C., Bistoni, F., Cassone, A., & Vecchiarelli, A. (2007) · Infection and Immunity · doi:10.1128/iai.00278-07 · Cited by 165
Extensive loss of cell-cycle and DNA repair genes in an ancient lineage of bipolar budding yeasts
Steenwyk, J. L., Opulente, D. A., Kominek, J., Shen, X.-X., Zhou, X., Labella, A. L., Bradley, N. P., Eichman, B. F., Čadež, N., Libkind, D., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000255 · Cited by 162
Population genomics and the evolution of virulence in the fungal pathogen Cryptococcus neoformans
Desjardins, C. A., Giamberardino, C., Sykes, S. M., Yu, C.-H., Tenor, J. L., Chen, Y., Yang, T., Jones, A. M., Sun, S., Haverkamp, M. R., et al. (2017) · Genome Research · doi:10.1101/gr.218727.116 · Cited by 157
Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A. M., Naseem, S., Konopka, J. B., Ojima, I., Büllesbach, E. E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 150
Hagen, F., Lumbsch, H. T., Arsić-Arsenijević, V. S., Badali, H., Bertout, S., Billmyre, R. B., Bragulat, M. R., Cabañes, F. J., Carbia, M., Chakrabarti, A., et al. (2017) · mSphere · doi:10.1128/msphere.00238-17 · Cited by 148
Virulence-Associated Enzymes of Cryptococcus neoformans
Almeida, F., Wolf, J. M., & Casadevall, A. (2015) · Eukaryotic Cell · doi:10.1128/ec.00103-15 · Cited by 141
Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1856 · Cited by 139
Dark chemical matter as a promising starting point for drug lead discovery
Wassermann, A. M., Lounkine, E., Hoepfner, D., Goff, G. L., King, F. J., Studer, C., Peltier, J. M., Grippo, M. L., Prindle, V. C., Tao, J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1936 · Cited by 138
Fan, Y., & Lin, X. (2018) · Genetics · doi:10.1534/genetics.117.300656 · Cited by 136
Dromer, F., Salamero, J., Contrepois, A., Carbon, C., & Yeni, P. (1987) · Infection and Immunity · doi:10.1128/iai.55.3.742-748.1987 · Cited by 128
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124
Self-citationUpadhya, R., Lam, W. C., Maybruck, B. T., Specht, C. A., Levitz, S. M., & Lodge, J. K. (2016) · mBio · doi:10.1128/mbio.00547-16 · Cited by 122
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Okagaki, L. H., Wang, Y., Ballou, E. R., O'Meara, T. R., Bahn, Y.-S., Alspaugh, J. A., Xue, C., & Nielsen, K. (2011) · Eukaryotic Cell · doi:10.1128/ec.05179-11 · Cited by 117
Juvvadi, P. R., Lamoth, F., & Steinbach, W. J. (2014) · Fungal Biology Reviews · doi:10.1016/j.fbr.2014.02.004 · Cited by 116
Juvvadi, P. R., Fox, D., Bobay, B. G., Hoy, M. J., Gobeil, S. M. C., Venters, R. A., Chang, Z., Lin, J. J., Averette, A. F., Cole, D. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12199-1 · Cited by 116
Comparative genomics allowed the identification of drug targets against human fungal pathogens
Abadio, A. K. R., Kioshima, É. S., Teixeira, M. D. M., Martins, N. F., Maigret, B., & Felipe, M. S. S. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-75 · Cited by 114
Gilbert, N. M., Donlin, M. J., Gerik, K. J., Specht, C. A., Djordjevic, J. T., Wilson, C. F., Sorrell, T. C., & Lodge, J. K. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07119.x · Cited by 113
Sionov, E., Chang, Y. C., & Kwon-Chung, K. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00694-13 · Cited by 112
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Dolan, K., Montgomery, S., Buchheit, B., DiDone, L., Wellington, M., & Krysan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01564-08 · Cited by 112
Noverr, M. C., Williamson, P. R., Fajardo, R. S., & Huffnagle, G. B. (2004) · Infection and Immunity · doi:10.1128/iai.72.3.1693-1699.2004 · Cited by 112
Butts, A., Koselny, K., Chabrier-Roselló, Y., Semighini, C. P., Brown, J. C. S., Wang, X., Annadurai, S., DiDone, L., Tabroff, J., Childers, W. E., et al. (2014) · mBio · doi:10.1128/mbio.00765-13 · Cited by 102
Intracellular Action of a Secreted Peptide Required for Fungal Virulence
Homer, C. M., Summers, D., Goranov, A. I., Clarke, S., Wiesner, D. L., Diedrich, J. K., Moresco, J. J., Toffaletti, D. L., Upadhya, R., Caradonna, I. I., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.001 · Cited by 102
Billmyre, R. B., Applen Clancey, S., Li, L. X., Doering, T. L., & Heitman, J. (2020) · Nature Communications · doi:10.1038/s41467-019-13890-z · Cited by 102
McClelland, E. E., Nicola, A. M., Prados-Rosales, R., & Casadevall, A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38322 · Cited by 101
Boyce, K. J., Wang, Y., Verma, S., Shakya, V. P. S., Xue, C., & Idnurm, A. (2017) · mBio · doi:10.1128/mbio.00595-17 · Cited by 101
Rhodes, J., Beale, M. A., Vanhove, M., Jarvis, J. N., Kannambath, S., Simpson, J. A., Ryan, A., Meintjes, G., Harrison, T. S., Fisher, M. C., et al. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.037499 · Cited by 100
Wozniak, K. L., Ravi, S., Macias, S., Young, M. L., Olszewski, M. A., Steele, C., & Wormley, F. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006854 · Cited by 99
Butts, A., DiDone, L., Koselny, K., Baxter, B. K., Chabrier-Rosello, Y., Wellington, M., & Krysan, D. J. (2013) · Eukaryotic Cell · doi:10.1128/ec.00314-12 · Cited by 95
The capsular dynamics of Cryptococcus neoformans
McFadden, D., Zaragoza, O., & Casadevall, A. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.09.003 · Cited by 93
Specht, C. A., Lee, C. K., Huang, H., Hester, M. M., Liu, J., Luckie, B. A., Torres Santana, M. A., Mirza, Z., Khoshkenar, P., Abraham, A., et al. (2017) · mBio · doi:10.1128/mbio.01872-17 · Cited by 91
Loyse, A., Burry, J., Cohn, J., Ford, N., Chiller, T., Ribeiro, I., Koulla-Shiro, S., Mghamba, J., Ramadhani, A., Nyirenda, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30493-6 · Cited by 90
Siafakas, A. R., Sorrell, T. C., Wright, L. C., Wilson, C. F., Larsen, M., Boadle, R. A., Williamson, P. R., & Djordjevic, J. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707913200 · Cited by 88
Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans
Huang, W., Liao, G., Baker, G. M., Wang, Y., Lau, R., Paderu, P., Perlin, D. S., & Xue, C. (2016) · mBio · doi:10.1128/mbio.00478-16 · Cited by 88
Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy515 · Cited by 86
Rella, A., Mor, V., Farnoud, A. M., Singh, A., Shamseddine, A. A., Ivanova, E., Carpino, N., Montagna, M. T., Luberto, C., & Poeta, M. D. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00836 · Cited by 85
Lee, H., Chang, Y. C., Nardone, G. A., & Kwon-Chung, K. J. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05666.x · Cited by 85
Stress Signaling Pathways for the Pathogenicity of Cryptococcus
Bahn, Y.-S., & Jung, K.-W. (2013) · Eukaryotic Cell · doi:10.1128/ec.00218-13 · Cited by 84
Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84
Correction: Fungal Cell Gigantism during Mammalian Infection
Zaragoza, O., García-Rodas, R., Nosanchuk, J. D., Cuenca-Estrella, M., Rodríguez-Tudela, J. L., & Casadevall, A. (2010) · PLoS Pathogens · doi:10.1371/annotation/0675044c-d80f-456f-bb63-4f85fb1d0c33 · Cited by 83
Upadhya, R., Baker, L. G., Lam, W. C., Specht, C. A., Donlin, M. J., & Lodge, J. K. (2018) · mBio · doi:10.1128/mbio.02087-18 · Cited by 83
Fungal kinases and transcription factors regulating brain infection in Cryptococcus neoformans
Lee, K.-T., Hong, J., Lee, D., Lee, M., Cha, S., Lim, Y.-G., Jung, K.-W., Hwangbo, A., Lee, Y., Yu, S.-J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15329-2 · Cited by 83
Mutators and sex in bacteria: Conflict between adaptive strategies
Tenaillon, O., Nagard, H. L., Godelle, B., & Taddéi, F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180063397 · Cited by 82
Singh, A., Wang, H., Silva, L. C., Na, C., Prieto, M., Futerman, A. H., Luberto, C., & Del Poeta, M. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01735.x · Cited by 81
Mukaremera, L., Lee, K. K., Wagener, J., Wiesner, D. L., Gow, N. A. R., & Nielsen, K. (2018) · The Cell Surface · doi:10.1016/j.tcsw.2017.12.001 · Cited by 80
Zhai, B., Wozniak, K. L., Masso-Silva, J. A., Upadhyay, S., Hole, C. R., Rivera, A., Wormley, F. L., & Lin, X. (2015) · mBio · doi:10.1128/mbio.01433-15 · Cited by 79
Microevolution of Serial Clinical Isolates ofCryptococcus neoformansvar.grubiiandC. gattii
Chen, Y., Farrer, R. A., Giamberardino, C. D., Sakthikumar, S., Jones, A., Yang, T., Tenor, J. L., Wagih, O., Wyk, M. V., Govender, N. P., et al. (2017) · mBio · doi:10.1128/mbio.00166-17 · Cited by 79
Billmyre, R. B., Clancey, S. A., & Heitman, J. (2017) · eLife · doi:10.7554/elife.28802 · Cited by 79
Cryptococcus neoformans of Unusual Morphology
Cruickshank, J. G., Cavill, R. H., & Jelbert, M. (1973) · Applied Microbiology · doi:10.1128/am.25.2.309-312.1973 · Cited by 78
Robbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Self-citationAn efficiently regulated promoter system for Cryptococcus neoformans utilizing the CTR4 promoter
Ory, J. J., Griffith, C. L., & Doering, T. L. (2004) · Yeast · doi:10.1002/yea.1139 · Cited by 78
A titanic drug resistance threat in Cryptococcus neoformans
Zafar, H., Altamirano, S., Ballou, E. R., & Nielsen, K. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.11.001 · Cited by 76
Protective Immunity against Experimental Pulmonary Cryptococcosis in T Cell-Depleted Mice
Wozniak, K. L., Young, M. L., & Wormley, F. L. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00036-11 · Cited by 72
Bastos, R. W., Carneiro, H. C. S., Oliveira, L. V. N., Rocha, K. M., Freitas, G. J. C., Costa, M. C., Magalhães, T. F. F., Carvalho, V. S. D., Rocha, C. E., Ferreira, G. F., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01179-17 · Cited by 72
Correction: Cryptococcal Cell Morphology Affects Host Cell Interactions and Pathogenicity
Okagaki, L. H., Strain, A. K., Nielsen, J. N., Charlier, C., Baltes, N. J., Chrétien, F., Heitman, J., Dromer, F., & Nielsen, K. (2010) · PLoS Pathogens · doi:10.1371/annotation/1b59fd9e-9ac9-4ea8-a083-14c413c80b03 · Cited by 71
Wang, Y., Wang, K., Masso-Silva, J. A., Rivera, A., & Xue, C. (2019) · mBio · doi:10.1128/mbio.02145-19 · Cited by 68
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis
Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K. M., Elsegeiny, W., Park, Y.-D., Atakulu, L., et al. (2019) · mBio · doi:10.1128/mbio.00724-19 · Cited by 67
Klutts, J. S., & Doering, T. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708927200 · Cited by 66
Gusa, A., Williams, J. D., Cho, J.-E., Averette, A. F., Sun, S., Shouse, E. M., Heitman, J., Alspaugh, J. A., & Jinks-Robertson, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001451117 · Cited by 65
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
Ianiri, G., & Idnurm, A. (2015) · mBio · doi:10.1128/mbio.02334-14 · Cited by 63
Cordeiro, R. D. A., Evangelista, A. J. D. J., Serpa, R., Marques, F. J. D. F., Melo, C. V. S. D., Oliveira, J. S. D., Franco, J. D. S., Alencar, L. P. D., Bandeira, T. D. J. P. G., Brilhante, R. S. N., et al. (2016) · Microbiology · doi:10.1099/mic.0.000222 · Cited by 63
Wambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors
Huang, D. S., LeBlanc, E. V., Shekhar‐Guturja, T., Robbins, N., Krysan, D. J., Pizarro, J. C., Whitesell, L. J., Cowen, L. E., & Brown, L. E. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00826 · Cited by 63
Self-citationA Call to Arms: Quest for a Cryptococcal Vaccine
Caballero Van Dyke, M. C., & Wormley, F. L. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.002 · Cited by 61
In VitroandIn VivoAssessment of FK506 Analogs as Novel Antifungal Drug Candidates
Lee, Y., Lee, K.-T., Lee, S. J., Beom, J. Y., Hwangbo, A., Jung, J. A., Song, M., Yoo, Y. J., Kang, S. H., Averette, A. F., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-18 · Cited by 58
Chatterjee, S., & Tatu, U. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005836 · Cited by 57
Wright, L. C., Santangelo, R. M., Ganendren, R., Payne, J., Djordjevic, J. T., & Sorrell, T. C. (2007) · Eukaryotic Cell · doi:10.1128/ec.00262-06 · Cited by 56
Ngamskulrungroj, P., Chang, Y., Hansen, B., Bugge, C., Fischer, E., & Kwon-Chung, K. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033022 · Cited by 56
Chayakulkeeree, M., Rude, T. H., Toffaletti, D. L., & Perfect, J. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00442-07 · Cited by 56
Evans, R. J., Li, Z., Hughes, W. S., Djordjevic, J. T., Nielsen, K., & May, R. C. (2015) · Infection and Immunity · doi:10.1128/iai.03104-14 · Cited by 53
Bowen, A., Wear, M. P., Cordero, R. J. B., Oscarson, S., & Casadevall, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767582 · Cited by 51
Lee, H., Lamichhane, A. K., Garraffo, H. M., Kwon-Chung, K. J., & Chang, Y. C. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08016.x · Cited by 50
Discovery of a Novel Antifungal Agent in the Pathogen Box
Mayer, F. L., & Kronstad, J. W. (2017) · mSphere · doi:10.1128/msphere.00120-17 · Cited by 49
Rossi, S. A., de Oliveira, H. C., Agreda-Mellon, D., Lucio, J., Mendes-Giannini, M. J. S., García-Cambero, J. P., & Zaragoza, O. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01921-19 · Cited by 48
Old Cryptococcus neoformans Cells Contribute to Virulence in Chronic Cryptococcosis
Bouklas, T., Pechuan, X., Goldman, D. L., Edelman, B., Bergman, A., & Fries, B. C. (2013) · mBio · doi:10.1128/mbio.00455-13 · Cited by 46
Altamirano, S., Fang, D., Simmons, C., Sridhar, S., Wu, P., Sanyal, K., & Kozubowski, L. (2017) · mSphere · doi:10.1128/msphere.00205-17 · Cited by 46
Cao, C., Wang, Y., Husain, S., Soteropoulos, P., & Xue, C. (2019) · mBio · doi:10.1128/mbio.01952-19 · Cited by 45
Park, Y., Shin, S., Panepinto, J. C., Ramos, J., Qiu, J. F., Frasés, S., Albuquerque, P., Cordero, R. J. B., Zhang, N., Himmelreich, U., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004037 · Cited by 44
Montoya, M. C., Beattie, S., Alden, K. M., & Krysan, D. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-19 · Cited by 42
Robbins, N., Spitzer, M., Wang, W., Waglechner, N., Patel, D. J., O’Brien, J. S., Ejim, L., Ejim, O., Tyers, M., & Wright, G. D. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.08.015 · Cited by 41
Self-citationPianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
Advances in fungal chemical genomics for the discovery of new antifungal agents
Xue, A., Robbins, N., & Cowen, L. E. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14484 · Cited by 41
Self-citationGarvey, E. P., Sharp, A. D., Warn, P. A., Yates, C. M., & Schotzinger, R. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky242 · Cited by 39
de Oliveira, H. C., Joffe, L. S., Simon, K. S., Castelli, R. F., Reis, F. C. G., Bryan, A. M., Borges, B. S., Medeiros, L. C. S., Bocca, A. L., Poeta, M. D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00286-20 · Cited by 37
Hole, C. R., & Wormley, F. L. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00291 · Cited by 36
So, Y.-S., Lee, D.-G., Idnurm, A., Ianiri, G., & Bahn, Y.-S. (2019) · Genetics · doi:10.1534/genetics.119.302191 · Cited by 36
Rapid mapping of insertional mutations to probe cell wall regulation in Cryptococcus neoformans
Esher, S. K., Granek, J. A., & Alspaugh, J. A. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.06.003 · Cited by 35
Bastos, R. W., Freitas, G. J. C., Carneiro, H. C. S., Oliveira, L. V. N., Gouveia-Eufrasio, L., Santos, A. P. N., Moyrand, F., Maufrais, C., Janbon, G., & Santos, D. A. (2019) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.05.094 · Cited by 35
Chang, Y. C., Khanal Lamichhane, A., & Kwon-Chung, K. J. (2018) · mBio · doi:10.1128/mbio.01290-18 · Cited by 34
A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans
Rabjohns, J. L. A., Park, Y.-D., Dehdashti, J., Sun, W., Henderson, C., Zelazny, A., Metallo, S. J., Zheng, W., & Williamson, P. R. (2014) · SLAS Discovery · doi:10.1177/1087057113496847 · Cited by 33
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., Chau, N. V. V., Binh, T. Q., Hung, L. Q., Beardsley, J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15010.1 · Cited by 28
Three galactose inducible promoters for use in C. neoformans var. grubii
RUFF, J., Lodge, J. K., & Baker, L. G. (2008) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.10.003 · Cited by 27
Hartland, K., Pu, J., Palmer, M., Dandapani, S., Moquist, P. N., Munoz, B., DiDone, L., Schreiber, S. L., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00111 · Cited by 24
Park, Y., Sun, W., Salas, A., Antia, A., Carvajal, C., Wang, A., Xu, X., Meng, Z., Zhou, M., Tawa, G. J., et al. (2016) · mBio · doi:10.1128/mbio.01073-16 · Cited by 21
Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box
Jung, E. H., Meyers, D. J., Bosch, J., & Casadevall, A. (2018) · mSphere · doi:10.1128/msphere.00537-17 · Cited by 21
Córdoba, S., Afeltra, J., & Vitale, R. G. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.08.003 · Cited by 17
Boyce, K. J., Cao, C., Xue, C., & Idnurm, A. (2020) · DNA Repair · doi:10.1016/j.dnarep.2019.102751 · Cited by 14
Functional Profiling of Human Fungal Pathogen GenomesPreprint
Goranov, A. I., & Madhani, H. D. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019596 · Cited by 13
Thiazole derivatives act on virulence factors of Cryptococcus spp.
de Sá, N. P., de Barros, P. P., Junqueira, J. C., Vaz, J. A., de Oliveira, R. B., Rosa, C. A., Santos, D. A., & Johann, S. (2019) · Medical Mycology · doi:10.1093/mmy/myx158 · Cited by 13
Nakamura, S., Ikeda-Dantsuji, Y., Jin, L., Higashi, Y., Abe, M., Inukai, T., Nagi, M., Urai, M., & Miyazaki, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02364-18 · Cited by 10
Beattie, S. R., Schnicker, N. J., Murante, T., Kettimuthu, K., Williams, N. S., Gakhar, L., & Krysan, D. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00478 · Cited by 10
Zhao, Q., Wei, D., Li, Z., Wang, Y., Zhu, X., & Zhu, X. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov086 · Cited by 8
Pharmacological inhibition of pigmentation inCryptococcus
Zimbres, A. C. G., Reuwsaat, J. C. V., Barcellos, V. A., Joffe, L. S., Fonseca, F. L., Staats, C. C., Schrank, A., Kmetzsch, L., Vainstein, M. H., & Rodrigues, M. L. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy119 · Cited by 8
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Wambaugh, M. A., & Brown, J. C. S. (2018) · Journal of Visualized Experiments · doi:10.3791/57241 · Cited by 5
Lahiri, S., Banerjee, A., Bhutda, S., Palaniappan, M., Bahubali, V. H., Manjunath, N., Maji, S., & Siddaiah, N. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.06.001 · Cited by 4
Research works printed but not linked: 1
- Chen, Y. et al. Microevolution of serial clinical isolates of Cryptococcus neoformans var. grubii and C. gattii. mBio 8, e00166-17 (2017).
Cited by
Sorted by citations
Ali, A., Shah, T., Ullah, R., Zhou, P., Guo, M., Ovais, M., Tan, Z., & Rui, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629054 · Cited by 650
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
Self-citationFungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond
Bastos, R. W., Rossato, L. L., Goldman, G. H., & Santos, D. A. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010073 · Cited by 120
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 128
Self-citationAntifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 115
Metadata
- Authors
- Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Cowen, Leah E.
- Venue
- Nature Reviews Microbiology
- Published
- 2021-02-08
- Volume
- 19
- Issue
- 7
- Pages
- 454-466
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- PMC
- PMC7868659
- OpenAlex
- W3127236674
- Semantic Scholar
- b3debc518effc79a3f7043a7e5e11118b45e854d
- Cited by
- 363
- References
- 161
- Citations by year
- 2026: 50 · 2025: 84 · 2024: 82 · 2023: 55 · 2022: 55 · 2021: 35
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institute for Advanced Research
- National Institutes of Health (NIAID R21)
- Canadian Institutes of Health Research (FDN154288)
- National Institute of Allergy and Infectious Diseases (R01AI127375, R21AI141080, R01AI120958)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- cryptococcosis, cryptococcal meningitis, Cryptococcus neoformans, Cryptococcus gattii, antifungal resistance, echinocandins, combination therapy, stress response pathways, antifungal drug discovery, host-pathogen interaction
- MeSH terms
- Antifungal Agents, Cell Wall, Cryptococcosis, Cryptococcus, Drug Resistance, Fungal, Virulence Factors, Echinocandins, Fungal Capsules, Fungal Polysaccharides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
